Based on this information, we hypothesized that mesylate apatinib might upregulate miR-34a-5p and decrease HOXA13 levels, leading to the inhibition of tumorigenesis and the progression of synovial sarcoma. The gene discussed is HOXA13; the disease is synovial sarcoma.